Insider information pursuant to Article 17 MAR
Berlin, 23 July 2018. According to initial analyses, the business development of the Berlin based isotope specialists Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE0005659700) was significantly higher as of June 30, 2018 than the comparable value of the prior year. While sales of EUR 64.8 million were generated in 2017 with continuing operations, this value increased by 25 % to EUR 81.0 million as of the half-year reporting date in 2018. In the same period, the earnings from continuing operations increased by 31 % from EUR 1.25 to EUR 1.63 per share.
Since the 2018 half-year result contains only a few extraordinary effects and the good business development included almost all of the main product groups, the Executive Board now assumes that the consolidated earnings from continuing operations will increase by at least 15 % for the fiscal year 2018 compared to the prior year. The previous target of EUR 2.20 therefore increases to around EUR 2.50 per share.
The complete figures for the first half year 2018 will be published on 31 July 2018.
Eckert & Ziegler AG, Karolin Riehle, Investor Relations
Robert-Rössle-Str. 10, 13125 Berlin, Germany
Tel.: +49 (0) 30 / 94 10 84-138, [email protected], www.ezag.com
Eckert & Ziegler AG published this content on 23 July 2018 and is solely responsible for the information contained herein. Distributed by Public, unedited and unaltered, on 23 July 2018 15:17:06 UTC